GSK Australia
- The GSK shingles vaccine, Shingrix, will be available to eligible people via the National Immunisation Program (NIP) on 1 November 2023.
- There are more than four million Australians aged 65 years and over. Many of these will now be eligible for a new funded vaccine against shingles.
- Shingrix is the first non-live vaccine to be listed on the National Immunisation Program (NIP) for the prevention of shingles.1
- Shingrix is indicated for adults from the age of 50 years and above, and adults from the age of 18 years and above who are at increased risk of shingles.2*
/Public Release.
